1. Scrip

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

Mutation-Agnostic Treatment Advances

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Cancer Cells
Aptose reports promising results for triplet therapy for mutation-agnostic frontline AML. (Shutterstock)

New data from Aptose Biosciences’ Phase I/II TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) show patients receiving 40mg or 80mg of the once-daily, oral multi-kinase inhibitor tuspetinib (licensed from South Korea’s Hanmi Pharm) in combination with standard of care doses of venetoclax and azacitidine demonstrated promising activity and safety.

The triple therapy is being developed by the Toronto, Canada-based firm as a mutation-agnostic frontline treatment for newly diagnosed AML...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from Therapy Areas

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.